Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of adding motivational interviewing to antidepressant treatment for major depressive disorder in Hispanic adults.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Antidepressive Agents

Criteria

Inclusion Criteria:

• Self-identifies as Hispanic

• Meets Diagnostic and Statistical Manual, 4th edition criteria for major depressive disorder (MDD)

• Score of 16 or higher on Hamilton Depression Scale (HAM-D17) at study entry

• Willing to abstain from other psychotropic medications not included in the Texas Medication Algorithm (TMA) for depression, as clinically indicated, for the duration of the study. Zolpidem for insomnia will be allowed.

• Fluency in English or Spanish

Exclusion Criteria:

• Acute suicidality

• History of schizophrenia, bipolar affective disorder, schizoaffective disorder, depression with psychotic features, or organic brain syndromes

• Alcohol or other substance abuse or dependence (except nicotine) within 6 months prior to study entry

• Clinically unstable medical disease, including narrow-angle glaucoma or increased intra-ocular pressure

• Systemic blood pressure of 140/90 mm Hg or less

• Liver function test values two times above the normal level

• Pregnant or breastfeeding

• Sexually active women not using an effective method of birth control

• Current or past history of seizure disorder (except febrile seizure in childhood)

• Receiving effective medication for MDD

• Unable to tolerate or unwilling to accept drug-free period of varying length: 1 week for benzodiazepines taken as needed; 2 weeks for buspirone, lithium, anticonvulsants, stimulants, barbiturates, opiates, and regular-use benzodiazepines (except clonazepam); and 5 weeks for clonazepam

• Received electroconvulsive therapy (ECT) within 3 months prior to study entry

• Parkinson's disease, dementia of any type, or cognitive impairment